Baker Bros. Advisors SERA Position
ActiveBaker Bros. Advisors held their position in SERA PROGNOSTICS, INC. (SERA) in Q4 2025, holding $16.2M worth of shares across 5,498,170 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds SERA.
About SERA PROGNOSTICS, INC.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Full company profile →Short Interest
0.8%
3.4 days to cover
Baker Bros. Advisors SERA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 5,498,170 | — | $16.2M |
| Q3 2025 | Held | 5,498,170 | — | $16.8M |
| Q2 2025 | Held | 5,498,170 | — | $15.2M |
| Q1 2025 | Increased | 5,498,170 | +63,771 | $20.2M |
| Q4 2024 | Held | 5,434,399 | — | $44.2M |
| Q3 2024 | Held | 5,434,399 | — | $42.4M |
| Q2 2024 | Held | 5,434,399 | — | $32.2M |
| Q1 2024 | Held | 5,434,399 | — | $49.5M |
| Q4 2023 | Increased | 5,434,399 | +3,919,057 | $32.5M |
| Q3 2023 | Decreased | 1,515,342 | -262,093 | $2.8M |
| Q2 2023 | Decreased | 1,777,435 | -11,565 | $5.9M |
| Q1 2023 | New | 1,789,000 | +1,789,000 | $6.9M |
Frequently Asked Questions
Does Baker Bros. Advisors own SERA?
Yes. As of Q4 2025, Baker Bros. Advisors holds 5,498,170 shares of SERA PROGNOSTICS, INC. (SERA) valued at $16.2M. This data comes from their SEC 13F filing.
How many hedge funds own SERA?
2 specialist biotech hedge funds currently hold SERA, including RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy SERA?
Baker Bros. Advisors's position in SERA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's SERA position increasing or decreasing?
Baker Bros. Advisors held their SERA position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SERACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →